DANESE, Silvio
 Distribuzione geografica
Continente #
NA - Nord America 17996
EU - Europa 2545
AF - Africa 600
AS - Asia 325
Continente sconosciuto - Info sul continente non disponibili 44
SA - Sud America 40
OC - Oceania 29
Totale 21579
Nazione #
US - Stati Uniti d'America 17832
FI - Finlandia 638
NG - Nigeria 591
FR - Francia 401
DE - Germania 254
NL - Olanda 221
GB - Regno Unito 187
SE - Svezia 183
IT - Italia 174
CA - Canada 156
IE - Irlanda 124
BE - Belgio 119
TR - Turchia 96
IL - Israele 69
RO - Romania 46
A2 - ???statistics.table.value.countryCode.A2??? 41
CN - Cina 40
RU - Federazione Russa 37
CL - Cile 34
AU - Australia 27
ES - Italia 26
UA - Ucraina 26
GR - Grecia 23
IR - Iran 23
JP - Giappone 22
IN - India 21
PL - Polonia 20
NO - Norvegia 16
SG - Singapore 13
BD - Bangladesh 11
AT - Austria 9
CH - Svizzera 9
MD - Moldavia 9
DK - Danimarca 7
MX - Messico 7
AE - Emirati Arabi Uniti 5
EG - Egitto 5
HK - Hong Kong 4
IQ - Iraq 4
SA - Arabia Saudita 4
BR - Brasile 3
EU - Europa 3
HU - Ungheria 3
MO - Macao, regione amministrativa speciale della Cina 3
AL - Albania 2
KR - Corea 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
ID - Indonesia 1
KE - Kenya 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MT - Malta 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UG - Uganda 1
VE - Venezuela 1
Totale 21579
Città #
Chandler 4195
Wilmington 4037
San Mateo 1634
Ann Arbor 1257
Lawrence 713
Princeton 713
Leawood 704
Helsinki 638
Benin City 590
Paris 387
Woodbridge 378
Fairfield 364
Boardman 296
Amsterdam 212
London 151
Toronto 135
Dublin 121
Seattle 117
Brussels 113
Norwalk 103
San Diego 93
Kocaeli 92
Milan 60
Redwood City 46
Monmouth Junction 36
Falls Church 34
Abbiategrasso 33
Clearwater 33
Cambridge 30
Houston 25
Des Moines 24
Redmond 21
Hanover 15
Phoenix 15
Las Vegas 13
Falkenstein 12
Shanghai 12
Beijing 11
Gunzenhausen 11
Raleigh 10
Andover 9
Chisinau 9
Duncan 9
La Canada Flintridge 9
Novokuznetsk 9
Ashburn 8
Kemerovo 8
Dallas 7
Sacramento 7
Zhengzhou 7
Cupertino 6
Henderson 6
Reghin 6
St Louis 6
Leipzig 5
Pitesti 5
Saint Louis 5
Winnipeg 5
Apo 4
Athens 4
Buffalo 4
Cairo 4
Glasgow 4
Köln 4
Madrid 4
New York 4
Ottawa 4
Saint Paul 4
San Pedro 4
Vancouver 4
Adliswil 3
Alexandria 3
Augusta 3
Berlin 3
Collegeville 3
Columbus 3
Groningen 3
Hyderabad 3
La Neuveville 3
Leninsk-kuznetskiy 3
Los Angeles 3
Padova 3
Penrith 3
Polska 3
Tokyo 3
Vienna 3
Zanjan 3
Alzate Brianza 2
Atlanta 2
Auckland 2
Basra 2
Belovo 2
Bitola 2
Bollebygd 2
Budapest 2
Büdelsdorf 2
Central District 2
Dhaka 2
Erlangen 2
Frankfurt am Main 2
Totale 17735
Nome #
Biological agents for ulcerative colitis : Hypes and hopes 239
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion 168
Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial 146
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 65
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer 58
Adalimumab in ulcerative colitis: Ready for prime time 58
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment 54
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis 54
IBD Of mice and men-shedding new light on IL-13 activity in IBD 53
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 53
Evolving strategies and goals of treatment in ulcerative colitis 52
Thrombomodulin-activated protein C-endothelial protein C receptor pathway: A novel anti-inflammatory system in IBD 52
Colitis-associated cancer: the dark side of inflammatory bowel disease 52
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease 52
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 51
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice 51
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 51
Association between Helicobacter pylori CagA-positive strains and ischemic stroke. 50
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study 50
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients 49
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 49
Dysregulated intracellular redox equilibrium in intestinal lamina propria T cells (LPT) contributes to mucosal inflammation 49
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 49
Effect of Tumor Necrosis Factor-alpha Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease 49
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 48
Correlation between delta(CO2)-C-13 excretion and prevalence of dyspeptic symptoms in subjects evaluated for H. pylori infection by C-13-urea breath test 48
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis 48
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response 48
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 47
Enhanced platelet adhesion induces angiogenesis in the IBD microcirculation 47
Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? 47
Laparoscopic Surgery for Recurrent Crohn's Disease 47
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 47
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 47
Stopping infliximab in crohn's disease: Still an ongoing STORI 47
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer 47
Methotrexate for Corticosteroid- Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial 47
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 47
Crohn's disease 47
Editorial: to facitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply 46
Helicobacter pylori infection in rheumatoid arthritis - Reply 46
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 46
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 46
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (R) (Cortiment (R)(MMX (R))) for active, mild-to-moderate ulcerative colitis 46
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate. 46
Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases 46
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 45
Ulcerative Colitis 45
Preventing disability in inflammatory bowel disease 45
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 45
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 45
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease 45
Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease 45
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 45
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations 44
Budesonide : teaching an old dog new tricks for inflammatory bowel disease treatment 44
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) 44
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 44
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes 44
Ustekinumab in the management of Crohn's disease: Expert opinion 44
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 44
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 44
Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease 44
Effect of Oral Administration of Methylene Blue MMx (R) Tablets on Double-Stranded DNA Damage Assessed by gamma H2AX Analysis of Colon Biopsy Samples - A Single Center, Open Label, Safety, Phase II Study 44
Association between Helicobacter pylori cytotoxic type I strains and migraine with aura 44
Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease 44
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 44
Biological therapies for inflammatory bowel disease: Research drives clinics 43
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease 43
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 43
Emerging therapeutic targets and strategies in Crohn's disease 43
High prevalence of infection by H. pylori cytotoxic type I strains in recurrent spontaneous abortion 43
Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach 43
The nocebo effect: a clinical challenge in the era of biosimilars 43
Balanced propofol sedation administered by nonanesthesiologists : the first Italian experience 43
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 43
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 43
Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside 43
Clinical development of biologicals and biosimilars - safety concerns 43
Regulation of leukocyte recruitment by the long pentraxin PTX3. 43
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal 42
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 42
Preventing Diverticulitis Recurrence by Selecting the Right Therapy for a Complex Disease 42
Microscopic features of colorectal neoplasia in inflammatory bowel diseases 42
Risk of postoperative recurrence and postoperative management of Crohn's disease 42
Assessment and grading of mucosal inflammation in colonic diverticular disease 42
Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects 42
Chemokines in inflammatory bowel disease 42
Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies 42
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis 42
Adalimumab in active ulcerative colitis: A "real-life" observational study 42
Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer : a case report 42
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 42
Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis 42
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target 42
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 41
Surgical rates in the era of biological therapy: up, down or unchanged? 41
Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease 41
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 41
Totale 5022
Categoria #
all - tutte 121106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121106

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202094 0000 00 00 00292
2020/20217431 401144976 362221 1007529 148498225868
2021/20224328 21955133872 3948 127555 392708945235
2022/202310409 160844310601208 899954 42949 18378785310
Totale 22262